Fundraising Fox
Precision Epigenomics
Tucson, US · Founded 2021 · Delaware corporation
Find your way into Precision Epigenomics
Sign up to see every warm intro you have to Precision Epigenomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Precision Epigenomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Precision Epigenomics develops EPISEEK, a blood-based multi-cancer early detection test that analyzes hypermethylated DNA loci to identify DNA changes linked to over 60 cancer types before symptoms appear. The test serves higher-risk individuals, health-conscious people aged 45+, healthcare providers, and wellness programs, with lab analysis performed at a CAP-accredited, CLIA-certified lab.
Founders & leadership
LJ
Lisa Jensen-LongExecutive
MH
Matthew H MillerExecutive
MA
Mark A NelsonNamed on SEC filing
BW
Barnard W FutscherNamed on SEC filing
MW
Marie WesselhoftNamed on SEC filing
BW
Bernard W FutscherNamed on SEC filing
Board
LS
Lisa ShafferBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 2 rounds · 2024–2025
▶$265KraisedSep 2025 · 5 investors · BiotechnologyRule 506(b)
▶$265KraisedSep 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ShafferDirector
- Mark A NelsonExecutive Officer, Director
- Lisa Jensen-LongExecutive Officer
- Barnard W FutscherExecutive Officer
- Matthew H MillerExecutive Officer
- Richard BernertExecutive Officer, Director
- Marie WesselhoftDirector
- Offering amount
- $2M
- Amount sold
- $265K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedApr 2024 · 2 investors · BiotechnologyRule 506(c)
▶$1.1MraisedApr 2024 · 2 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Richard BernertExecutive Officer, Director
- Bernard W FutscherExecutive Officer
- Lisa ShafferDirector
- Mark A NelsonExecutive Officer, Director
- Marie WesselhoftDirector
- Lisa Jensen-LongExecutive Officer
- Matthew H MillerExecutive Officer
- Offering amount
- $1.7M
- Amount sold
- $1.1M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Epigenic TherapeuticsEpigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence. Combined with a lipid nanoparticle delivery system, the technology targets metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases.
Exact SciencesExact Sciences develops molecular diagnostic tests for cancer screening and detection, including multitarget stool DNA testing for colorectal cancer and multigene assays for breast cancer recurrence. The company serves patients and healthcare providers in the cancer diagnostics field.
GeneseeqGeneseeq develops next-generation sequencing (NGS) based genetic tests and in-vitro diagnostic products for cancer patients, using gene profiling to guide targeted drug selection, indicate drug resistance mechanisms, and monitor post-surgical recurrence. It also works on early cancer screening and provides molecular diagnostic services and pharmaceutical partnership/companion diagnostics for precision oncology.
Epi BiologicsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Companies working in the same space as Precision Epigenomics.
Frequently asked questions
- What does Precision Epigenomics do?
- Precision Epigenomics develops EPISEEK, a blood-based multi-cancer early detection test that analyzes hypermethylated DNA loci to identify DNA changes linked to over 60 cancer types before symptoms appear. The test serves higher-risk individuals, health-conscious people aged 45+, healthcare providers, and wellness programs, with lab analysis performed at a CAP-accredited, CLIA-certified lab.
- How much funding has Precision Epigenomics raised?
- Precision Epigenomics has disclosed $1.4M raised across 2 rounds.
- Where is Precision Epigenomics headquartered?
- Precision Epigenomics is headquartered in Tucson, US.